Latest C-peptide Stories

C-peptide production and beta cell functioning detected decades after disease onset Massachusetts General Hospital (MGH) research has found that insulin production may persist for decades after the onset of type 1 diabetes. Beta cell functioning also appears to be preserved in some patients years after apparent loss of pancreatic function. "Traditionally, it was thought that beta cell function completely ceased in patients with advanced type 1 diabetes. However, data from this study and...

BOONTON, N.J., Feb. 8, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), today announced the expansion of its Biotechnologies strategic business unit (SBU) with the promotion of Gregory T. Mayes, Esq. to the position of Chief Business Officer and the appointment of Jane Pepper, M.B.A, Ph.D. to Senior Director, Business Development. Mr. Mayes' promotion to Chief Business Officer extends a successful tenure at Unigene since his appointment to Vice President,...

LELYSTAD, The Netherlands, February 8, 2012 /PRNewswire/ -- Pepscan Therapeutics B.V., the Netherlands based biotechnology firm focusing on protein mimicry technology for the generation of novel therapeutics, today announced that it has achieved two milestones in the Research Collaboration with Janssen R&D Ireland, formerly Tibotec Pharmaceuticals, and received undisclosed payments. In the collaboration, Pepscan has discovered novel peptides with potential...

BOONTON, N.J., Jan. 11, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that it had been granted U.S. Patent No. 8,076,291 from the United States Patent and Trademark Office (USPTO). The patent, which was issued on December 13, 2011, provides intellectual property (IP) protection for peptides and pharmaceutical compositions containing such peptides for the...

BOONTON, N.J., Jan. 9, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today provided a business outlook for 2012 and highlighted multiple near-term catalysts that have the potential to monetize assets and unlock significant value over the next 12 months. Management believes the key elements are in place to address the Company's debt and begin restructuring the balance sheet in 2012. Unigene's CEO, Senior Management and Board of Directors signaled confidence...

BOONTON, N.J., Dec. 19, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today highlighted its significant accomplishments in 2011 and announced that its management team has put key elements in place to begin addressing the capital structure and eliminating the inherited debt. Unigene also reaffirmed that the Company's projected cash flow is expected to fund operations into the second half of 2012, following a corporate reorganization to better strategically...

CRANBURY, N.J., Nov. 30, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that Dr. Carl Spana, President and Chief Executive Officer, will be presenting at Windhover's Therapeutic Area Partnerships conference on Thursday, December 1, 2011. The conference will be held...

SEATTLE, Nov. 21, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application directed to increasing the plasma half-life of therapeutic proteins and peptides by recombinantly conjugating them to a novel, non-immunogenic peptide repeat sequence. The patent and its related technology are exclusively licensed to Aequus Biopharma, Inc. (Aequus), a majority...

Using Mendelian randomization, Roman Pfister of the University of Cambridge, UK and colleagues demonstrate a potentially causal link between low levels of B-type natriuretic peptide (BNP), a hormone released by damaged heart tissue, and the development of type 2 diabetes. The findings, published in this week's PLoS Medicine, suggest that BNP may be a potential target for interventions designed to prevent type 2 diabetes, particularly since the feasibility of altering BNP levels with drugs has...

Researchers may have found a specific dietary pattern linked to levels of C-peptide concentrations that increase a woman's risk for colorectal cancer. "High red meat intake, fish intake, sugar-sweetened beverage intake, but low coffee, whole grains and high-fat dairy intake, when taken as a whole, seemed to be associated with higher levels of C-peptide in the blood," said Teresa T. Fung, S.D., R.D., professor of nutrition at Simmons College in Boston, who presented the data at the 10th...